Anika Will Re-analyze Unfavorable Orthovisc Data, Look To Pipeline Products
This article was originally published in The Gray Sheet
Executive Summary
Bristol-Myers Squibb's Zimmer unit will continue to sell Anika Therapeutics' Orthovisc outside the U.S. and take a wait-and-see approach toward its contractual obligations in the U.S. while Anika analyzes unfavorable data generated in Phase III U.S. trials.
You may also be interested in...
Orthovisc Clinical Trial Data Filed With FDA; Will Third Time Prove A Charm?
Anika Therapeutics will seek a marketing partner to distribute its Orthovisc injectable hyaluronic acid if the knee osteoarthritis therapy is approved by FDA
Orthovisc Clinical Trial Data Filed With FDA; Will Third Time Prove A Charm?
Anika Therapeutics will seek a marketing partner to distribute its Orthovisc injectable hyaluronic acid if the knee osteoarthritis therapy is approved by FDA
Data Deficiencies Derail Lifecore Intergel Liquid Adhesion Barrier PMA
Higher than expected infection rates, pending safety data and lingering questions over clinical efficacy prompted FDA's General and Plastic Surgery Devices Panel to recommend against approval of Lifecore Biomedical's Intergel adhesion prevention barrier solution in a 5-2 vote during a Jan. 12 meeting in Rockville, Maryland.